K. TewthanomS. JanwitayanujitK. TotemchockcyakarnD. Panomvana Na AyudhyaSilpakorn UniversityMahidol UniversityChulalongkorn University2018-09-242018-09-242010-08-01Journal of Clinical Pharmacy and Therapeutics. Vol.35, No.4 (2010), 483-48513652710026947272-s2.0-77954507692https://repository.li.mahidol.ac.th/handle/20.500.14594/29580An imbalance of oxidative-antioxidant defence mechanism has been proposed in systemic lupus erythematosus patients. Co-administration of N-acetylcysteine (NAC) which has a strong antioxidant activity may produce a satisfactory therapeutic outcome when added to standard therapy. We report a case of a 46-year-old lupus nephritis patient who received 1800 mg of NAC orally. After NAC, this patient showed a higher glutathione level, and a normal level of malondialdehyde, a lipid peroxidation product. In addition, the urinary protein levels, the complete blood counts and physical examination of the affected organs showed improvement. However, a well-controlled trial is needed to confirm the value of high-dose NAC in lupus nephritis patients. © 2010 Blackwell Publishing Ltd.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1111/j.1365-2710.2009.01108.x